2023 Cannabis DEA Topical 
Canna Law Blog
MAY 29, 2024
In my June 2023 post, I concluded that even if there are good arguments for THCA’s legality, practically speaking law enforcement was likely to consider THCA in calculating total THC, given the fact that THCA converts to THC upon application of heat. But, it bears mentioning that DEA’s interpretations are just that.
Cannabis Law Report
AUGUST 12, 2022
Marijuana Moment report on some of the panels being proposed for 2023…… Voting is now open for the public to decide which panels will make the stage at next year’s South By Southwest (SXSW) festival—and there are about 100 marijuana- and psychedelics-related proposals to pick from. Is cannabis actually. Green or not?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
FEBRUARY 16, 2024
Griffen’s article is just one of many parsing the language of the 2018 Farm Bill and a 2023 DEA letter on the topic. See also: “ THCA and the DEA: Rod Breaks Down the Latest News ” from Rod Kight, an another attorney prominent in the space. But DEA is not a court and DEA hasn’t made a rule, either.
Canna Law Blog
APRIL 24, 2023
I wanted to drop a line today on an interesting piece of cannabis legislation moving through the Oregon legislative session. Note that hemp-derived topical products are excepted from the SB 353 regime. Suffice it to say that DEA has opined that it is — at least for now. Oregon’s legislative session ends June 25, 2023.
Cannabis Law Report
MAY 29, 2022
Celebrated author Michael Pollan has published two bestselling books on the topic: How to Change Your Mind and This is Your Mind on Plants. 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10]
Canna Law Blog
MAY 1, 2024
Yesterday, some big news dropped that the cannabis industry has anticipated since last summer. I take issue with some of the headlines , so here’s mine: “DEA Reportedly Agrees to Initiate Proposed Rulemaking to Reschedule Marijuana…”. HHS followed that directive, recommending on August 30, 2023, that marijuana be moved to Schedule III.
Cannabis Law Report
JUNE 1, 2021
Achieves 37% revenue growth in FY 2021 with strong double-digit growth across both cannabis and other consumer products businesses. Net revenue increased 37% during FY 2021 over the prior year driven by double-digit growth across Canadian cannabis, international cannabis and other consumer products businesses.
Expert insights. Personalized for you.
69 
Let's personalize your content